Valuation: Collegium Pharmaceutical, Inc.

Market Cap 701M 630M 588M 533M 1B 66.7B 1.01B 7.06B 2.76B 34.62B 2.63B 2.57B 111B P/E 2026 *
19.3x
P/E 2027 * 6.03x
Enterprise Value 1.55B 1.4B 1.3B 1.18B 2.22B 148B 2.23B 15.63B 6.1B 76.67B 5.83B 5.7B 247B EV / Sales 2026 *
1.86x
EV / Sales 2027 * 1.48x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day+3.32%
1 week+1.71%
Current month+2.22%
1 month-2.21%
3 months-36.31%
6 months-37.42%
Current year-51.83%
1 week 21.46
Extreme 21.46
22.56
1 month 21.43
Extreme 21.43
23.69
Current year 21.43
Extreme 21.43
49.31
1 year 21.43
Extreme 21.43
50.79
3 years 20.95
Extreme 20.95
50.79
5 years 14.04
Extreme 14.04
50.79
10 years 7.37
Extreme 7.37
50.79
Manager TitleAgeSince
Chief Executive Officer 51 12/11/2024
Director of Finance/CFO 50 24/05/2021
Chief Tech/Sci/R&D Officer 65 23/03/2022
Director TitleAgeSince
Chairman 69 15/05/2025
Director/Board Member 72 01/02/2014
Director/Board Member 78 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
18/5/26 Sell

Director

-20 0.0001%
15/5/26 Exercice

Director

21,527 0.0664%
14/5/26 Free

Director

8,741 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
+3.32%+1.71%-30.67%+1.62% 701M
+3.99%+2.17%+49.50%+96.95% 1,040B
+1.95%-2.10%+32.58%+60.62% 599B
+3.87%+4.97%+24.32%+93.48% 485B
+3.58%+3.35%+74.23%+41.71% 350B
+3.09%+3.03%+29.59%+47.09% 345B
+2.82%+2.20%+17.90%+40.67% 272B
+3.40%+0.99%-3.44%+12.10% 244B
+3.47%+3.43%+45.40%+48.93% 223B
+3.70%+4.49%+29.52%+93.75% 183B
Average +3.31%+1.98%+26.89%+53.69% 374.35B
Weighted average by Cap. +3.35%+2.31%+37.01%+68.25%

Financials

2026 *2027 *
Net sales 833M 749M 699M 634M 1.19B 79.28B 1.2B 8.39B 3.28B 41.15B 3.13B 3.06B 132B 845M 759M 709M 642M 1.21B 80.37B 1.21B 8.5B 3.32B 41.71B 3.17B 3.1B 134B
Net income 28.73M 25.83M 24.1M 21.84M 41.01M 2.73B 41.27M 289M 113M 1.42B 108M 106M 4.56B 83.33M 74.92M 69.92M 63.37M 119M 7.93B 120M 839M 328M 4.12B 313M 306M 13.24B
Net Debt 851M 765M 714M 647M 1.22B 81.02B 1.22B 8.57B 3.35B 42.05B 3.2B 3.13B 135B 553M 497M 464M 421M 790M 52.63B 795M 5.57B 2.17B 27.32B 2.08B 2.03B 87.86B
Projected Income Statement - Annual - Collegium Pharmaceutical, Inc.
Logo Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
Employees
423
Date Price Change Volume
15/10/26 USD 22.19 +3.07% 391,741
13/10/26 USD 21.53 -2.36% 846,421
12/10/26 USD 22.05 -0.18% 528,695
09/10/26 USD 22.09 -0.09% 438,440
08/10/26 USD 22.11 +0.82% 532,922
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Collegium Pharmaceutical, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
21.53USD
Average target price
49.00USD
Spread / Average Target
+127.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Collegium Pharmaceutical, Inc.
  1. Stock Market
  2. Stocks
  3. COLL Stock